News | March 04, 2021
COVAXIN demonstrates interim clinical efficacy of 81%
Bharat Biotech expects to share further details of the trial results as additional data become available.
Bharat Biotech expects to share further details of the trial results as additional data become available.
While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side
Applied Biosystems CoviPath COVID-19 RT-PCR Kit is approved for in vitro diagnostic use by ICMR and DCGI.
DHL and other logistics companies were already transporting pharmaceutical products at minus 70°C in Schaumaplast boxes packed with dry ice before the coronavirus pandemic
Dr. Reddy's will present the safety profile of the phase 2 study, and interim data of the phase 3 study, which is expected to complete by 2pt February 2021.
The jump in profit is due to the better performance of the API business.
EBITDA for the quarter stood at Rs. 427 crore and Net Profit was at Rs. 169 crore. Our Core EBITDA margins stood at 31%.
EBITDA and PAT for the quarter were both up 11% to Rs. 193 crores and Rs. 102 crores respectively.
The phase 3 clinical trial of Sputnik V will be conducted on 1,500 subjects as part of the randomized, double blind, parallel group placebo controlled study in India.
The company is expecting tremendous growth and a better quarterly performance
Subscribe To Our Newsletter & Stay Updated
